



Disclosure & Content Validity

The individuals in control of content for this activity have no relevant relationships with [ACCME-defined ineligible companies](#) to disclose unless listed below. All relevant relationships are mitigated in accordance with [The Standards for Integrity and Independence in Accredited Continuing Education](#) prior to the start of the activity.

Relevant relationships are listed below.

Anna Burgner— *Research Funding:* Bayer, ProKidney

Beatrice Concepcion – *Advisor:* Veloxis, Novartis; *Consultancy:* Ipsen pharmaceutical

Ronald Falk— *Consultancy:* Vertex Pharmaceuticals

David Goldfarb— *Ownership:* Moonstone Nutrition, Inc.,

Jay Koyner— *Consultancy:* Astute – Biomerieux, Bioporto, Fresenius - NxStage – FMC, Alexion, Seastar medical, Novartis, Guard Therapeutics; *Research Funding:* Astute – Biomerieux, Bioporto, Fresenius - NxStage – FMC; *Researcher:* Bioporto; *Advisor:* Alexion, Novartis, Astra-Zeneca; *Royalties/Patent Beneficiary:* Wolters Kluwer

Eleanor Lederer – *Royalties/Patent Beneficiary:* DOSIS

Kathleen Liu – *Consultancy:* UpToDate, Novartis, Lightening Health, Atom, Guard Pharmaceuticals, Regeneron; *Public Stock and/or Stock Options:* Amgen, 3M

Laura Mariani— *Consultancy:* Boehringer-Ingelheim, Vera, Novartis, Apellis, Travele Therapeutics, Dimerix; *Research Funding:* HiBio, Calliditas, Takeda Pharmaceuticals, Boehringer-Ingelheim, Travele Therapeutics, Reliant Glycosciences, Otsuka Pharmaceuticals; *Independent Contractor:* Apellis, Otsuka Pharmaceuticals

Glen Markowitz – *Advisor:* Amgen, Novartis

Ali Mehdi – *Speakers Bureau:* Alexion, GSK, Apellis; *Consultancy:* Alexion, Novartis, GSK; *Advisor:* Calliditas

Sankur Navaneethan – *Consultancy:* AstraZeneca, Bayer, Boehringer-Ingelheim, Alnylam, Intercept, Prokidney, Vertex, Novartis

Sarah Sanghavi— *Advisor:* Fresenius Medical Care

Ankur Shah – *Consultancy:* Otsuka

Scott Westphal— *Research Funding:* Transplant Genomics, Natera, Eledon, Inc., NefroHealth, Veloxis; *Advisor:* Thermo Fisher

William Whittier— *Research Funding:* Astellis, Novartis; *Advisor:* GlaxoSmithKline

Alexander Wiseman - *Speakers Bureau:* Veloxis, Takeda, Sanofi; *Consultancy:* Verici, Sanofi, Hansa, Pirche

Anna Zisman – *Consultancy:* NovoNordisk Rare Disease; *Speakers Bureau:* NovoNordisk Rare Disease